Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

Share Price is delayed by 15 minutes
Get Live Data
325.00    -8.00 (-2.40%)
Bid:
320.00
Ask:
330.00
Spread: 10.00 (3.125%)
Market Cap: £41.24m
SYS1 Live PriceLast checked at - London Stock Exchange

Intraday System1 Group Share Chart

Trading Update

19 Jan 2010 07:00

RNS Number : 7493F
BrainJuicer Group PLC
19 January 2010
Β 

ο»Ώ

Press releaseΒ 

19Β JanuaryΒ 2010

BrainJuicer Group PLC

("BrainJuicer" orΒ "theΒ Group"Β or "the Company")

TradingΒ Update

Profitable growth

Leading international online market researcher, BrainJuicer Group PLC, today gives the following update on trading ahead of its Preliminary ResultsΒ for the financial year ended 31 December 2009Β which will be announced onΒ 9Β March 2010.

Highlights:

Β 

Β·; Β 
Results expected to be in line with market expectations; profitable growth continues despite difficult market conditions and significant investment in product development, operations and technology
Β·;
Revenue up around 26% to approximately Β£11.7 million (2008: Β£9.3 million)
Β·;
Operating profit up by more than 25% to over Β£1.6 million (2008: Β£1.29 million)
Β·;
Strong financial position with cash up to around Β£2.3 million at 31 December 2009 (30 June 2009: Β£1.2m) and no debt
Β·;
Innovative β€˜Juicy’ products grew 65% to over 60% of turnover [2008: 46%]
Β·;
Working with 11 of the world’s top 20 buyers of market research [9 in 2008]
Β·;
Both new offices, Switzerland and Germany achieved profitability in their first 18 months

BrainJuicer's reputationΒ for innovationΒ grewΒ furtherΒ in 2009Β with revenue from the Group's strategically important 'Juicy' productsΒ making significant gainsΒ and now accounting for over 60% ofΒ the Group'sΒ revenue (2008: 46%).Β These products are being sold to some of the world's largest buyers of market research. In 2009Β the Company'sΒ clients included 11 of the world's top 20 buyers of market research, up from 9 in 2008, and revenue from these clients grew byΒ over 70%. Client satisfaction remains high with repeat business at around 80%.

RevenueΒ increaseΒ wasΒ driven by continued strong progress in theΒ US,Β growing at aroundΒ 60%,Β and byΒ veryΒ encouraging contributions fromΒ the new offices inΒ SwitzerlandΒ andΒ Germany. The Company'sΒ  UKΒ business recovered after a slow start toΒ theΒ yearΒ (revenue for the full year wasΒ aroundΒ 2%Β lower), andΒ Dutch revenue grewΒ aboutΒ 10%. Overall the Group achievedΒ approximatelyΒ 26% revenue growthΒ (21% on aΒ constantΒ currency basis).

Operating profitΒ isΒ upΒ by more thanΒ 25%Β whilst having at the sameΒ timeΒ invested more than ever before inΒ developing and validatingΒ products,Β inΒ back-office operations andΒ inΒ the Company'sΒ softwareΒ  platform. We believeΒ this investmentΒ will drive future growth.

The GroupΒ has reached an agreement to acquire High Level Research Inc., its Canadian licencee, for a nominal sum.Β Β This will be managed as a regional office within our North American business.

John Kearon,Β CEOΒ of BrainJuicer, commented: "To have grown so strongly in a year whenΒ spending onΒ market researchΒ seems to haveΒ declined for the first time in 25 years is a tremendous achievement and testament to the attraction of our innovative 'Juicy' products, expanded geographic footprint and talented researchers to our major multinational client base. Despite the dire economic conditions, we have continued to make significant investments.Β Β WhilstΒ manyΒ of the largest research agenciesΒ have apparentlyΒ declined and retrenched during 2009, we continued to invest heavily inΒ new and existing 'Juicy' products, enhancingΒ the efficiency and scalability ofΒ our technology platformΒ andΒ expanding our geographic footprint. These investmentsΒ will, we believe, enable us to secure the global and regional mandates which we need to fulfil our longer term ambitions.

"The Board isΒ confident that in 2010 we can continue to grow our businessΒ throughΒ  furtherΒ productΒ  innovationΒ andΒ increasing our market share withΒ major multinationalΒ customers."

An analyst presentation, given by John Kearon,Β CEO, and James Geddes, CFO, will be held at 9.30am onΒ 9Β March 2010 at Abchurch's office, 16thΒ Floor,Β 125 Old Broad Street,Β London,Β EC2N 1AR.

- Ends -

For further information, please contact:

BrainJuicer GroupΒ PLC

Tel: +44 (0)Β 20 7043 1000

John Kearon, Chief Executive Officer

john.kearon@brainjuicer.com

James Geddes, Chief Financial Officer

james.geddes@brainjuicer.com

Canaccord Adams

Tel: +44 (0)Β 20 7050 6500

Mark Williams /Β Henry Fitzgerald-O'Connor

www.canaccordadams.com

Media enquiries:

Abchurch Communications

Heather Salmond /Β Joanne Shears

Tel: +44 (0)Β 20 7398 7709

joanne.shears@abchurch-group.com

www.abchurch-group.com

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTUWOWRROAAAAR
Date   Source Headline
1st May 20264:30 pmRNSHolding(s) in Company
21st Apr 20267:01 amRNSRelationship Agreement with Brave Bison
21st Apr 20267:00 amRNSQ4 and Full Year Trading Update
9th Apr 20267:00 amRNS-RLaunch of next evolution of Test Your Ad platform
30th Mar 20264:30 pmRNSHolding(s) in Company
30th Mar 20263:30 pmRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSTrading Update
16th Mar 20267:00 amRNSTrading Update
5th Mar 20263:15 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:15 pmRNSHolding(s) in Company
3rd Mar 20264:06 pmRNSBoard Change
2nd Mar 20261:39 pmRNSShareholder update & PDMR Dealing
2nd Mar 20267:00 amRNSDirectorate change
30th Jan 20261:00 pmRNSBoard Committee and Change of Role Update
20th Jan 20267:00 amRNSTrading Update
12th Jan 20264:45 pmRNSAppointment of Joint Corporate Broker
2nd Dec 20257:00 amRNSInterim Results
20th Nov 202511:45 amRNSHolding(s) in Company
24th Oct 20253:28 pmRNSHolding(s) in Company
22nd Oct 20257:00 amRNSTrading Update
14th Oct 20259:16 amRNSCapital Markets Day
6th Oct 20253:30 pmRNSDirector/PDMR Shareholding
30th Sep 20257:00 amRNSDirector/PDMR Shareholding - replacement
29th Sep 20255:48 pmRNSDirector/PDMR Shareholding
29th Sep 20251:27 pmRNSHolding(s) in Company
26th Sep 20252:29 pmRNSHolding(s) in Company
26th Sep 20257:00 amRNSDirector/PDMR Shareholding
24th Sep 20253:01 pmRNSResult of AGM
23rd Sep 20257:00 amRNSTrading Update
15th Sep 20251:00 pmRNSDirector/PDMR Shareholding
27th Aug 20254:51 pmRNSNotice of AGM
8th Aug 20254:35 pmRNSDirector/PDMR Shareholding
9th Jul 20257:00 amRNSDirector Role Change
9th Jul 20257:00 amRNSFinal Results
9th Jul 20257:00 amRNSTrading Update
4th Jul 202511:45 amRNSHolding(s) in Company
4th Jul 20257:00 amRNSHolding(s) in Company
16th Jun 20251:30 pmRNSHolding(s) in Company
14th May 20257:00 amRNSEstablishment of New Long-Term Incentive Plan
24th Apr 20251:53 pmRNSHolding(s) in Company
23rd Apr 20257:00 amRNSTrading Statement
23rd Jan 20257:00 amRNSHolding(s) in Company
21st Jan 20257:00 amRNSTrading Update
8th Jan 202510:15 amRNSHolding(s) in Company
3rd Dec 20247:00 amRNSInterim Results
28th Nov 20247:00 amRNSInterim Results Presentation
21st Nov 20243:31 pmRNSHolding(s) in Company
28th Oct 202410:15 amRNSDirector/PDMR Shareholding
23rd Oct 20247:00 amRNSDirector/PDMR Shareholding
22nd Oct 20247:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.